Four-year durability of the Myval balloon-expandable transcatheter aortic valve
EuroIntervention · 2025-07 · 21 (13) · e758-e765
DOI: 10.4244/eij-d-24-01112 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift EuroIntervention, 2025-07. Verfasst von Akash Jain und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Heart Valve Prosthesis, Aortic Valve. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: The Myval series is the first commercially available balloon-expandable transcatheter aortic valve implantation (TAVI) system designed as an alternative to the SAPIEN series. The LANDMARK trial recently demonstrated its non-inferiority compared to contemporary systems. However, the long-term durability of the Myval series remains unknown. AIMS: We aimed to evaluate the 4-year durability of the Myval series using Valve Academic Research Consortium (VARC)-3-defined endpoints. METHODS: We carried out a multicentre ambispective study of patients with severe aortic stenosis who underwent TAVI with the Myval series between December 2017 and April 2020. Baseline characteristics were prospectively recorded in a dedicated database. Clinical and echocardiographic follow-up was performed at 4 years. Outcomes included haemodynamic valve deterioration (HVD), bioprosthetic valve failure (BVF), and patient-prosthesis mismatch (PPM) as defined by the VARC-3 criteria, assessed at a central echocardiography laboratory. RESULTS: A total of 366 patients from 9 institutions were included, all of whom completed 4-year follow-up or were followed up until death. The 4-year survival rate was 81.8%, with residual ≥moderate aortic regurgitation observed in 9.2% of patients. BVF criterion 1 (symptomatic valve failure) occurred in 3.3%, while no cases of BVF criteria 2 or 3 were reported. Stage 2 HVD was observed in 9.7% of patients and stage 3 HVD in 0.7% at 4 years. Moderate and severe PPM were identified in 3.6% and 2.1% of patients at 1 year, respectively. CONCLUSIONS: In a real-world cohort, 4-year outcomes with the balloon-expandable Myval series demonstrated acceptable valve durability, low haemodynamic deterioration, and comparable performance to contemporary TAVI systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
- Christian Medical College, Vellore, India.
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy and Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Odense University Hospital, Odense, Denmark.
- Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain.
- Fortis Escorts Heart Institute, New Delhi, India.
Zitieren
APA
Jain, A., Jose, J., Montorfano, M., Nissen, H., Martin, P., Seth, A., Stambuk, K., Sengottuvelu, G., Abdurashid, M., García-Gómez, M., Fernandez-Cordón, C., Rodriguez, M., Jorgensen, M. D., Campo, A., Serrador, A., Vallinas-Hernandez, S., Carrasco-Moraleja, M., San Román, A., & Amat-Santos, I. J. (2025). Four-year durability of the Myval balloon-expandable transcatheter aortic valve. EuroIntervention, 21(13), e758-e765. https://doi.org/10.4244/eij-d-24-01112
Vancouver
Jain A, Jose J, Montorfano M, Nissen H, Martin P, Seth A, et al. Four-year durability of the Myval balloon-expandable transcatheter aortic valve. EuroIntervention. 2025;21(13):e758-e765. doi:10.4244/eij-d-24-01112
BibTeX
@article{Jain2025,
author = {Jain, Akash and Jose, John and Montorfano, Matteo and Nissen, Henrik and Martin, Pedro and Seth, Ashok and Stambuk, Kresimir and Sengottuvelu, Gunasekaran and Abdurashid, Mussayev and García-Gómez, Mario and Fernandez-Cordón, Clara and Rodriguez, Marcelo and Jorgensen, Mathias D and Campo, Alberto and Serrador, Ana and Vallinas-Hernandez, Silvia and Carrasco-Moraleja, Manuel and San Román, Alberto and Amat-Santos, Ignacio J},
title = {Four-year durability of the Myval balloon-expandable transcatheter aortic valve},
journal = {EuroIntervention},
year = {2025},
volume = {21},
number = {13},
pages = {e758--e765},
doi = {10.4244/eij-d-24-01112}
}
EUVIMED